Entera Stock Financials

ENTX
 Stock
  

USD 1.88  0.10  5.62%   

Entera Bio Average Equity is fairly stable at the moment as compared to the past year. Entera Bio reported Average Equity of 20.37 Million in 2021. Working Capital is likely to rise to about 23.9 M in 2022, whereas Average Assets are likely to drop slightly above 21.7 M in 2022.
  
With this module, you can analyze Entera financials for your investing period. You should be able to track the changes in Entera Bio individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

Entera Most Recent Estimates

EPS Estimate Next Quarter
-0.21
Diluted Eps
-0.49
EPS Estimate Current Year
-0.66
EPS Estimate Next Year
-0.69
EPS Estimate Current Quarter
-0.18
Earnings Share
-0.49

Revenues

542,526

Understanding current and past Entera Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Entera Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Entera Bio's assets may result in an increase in income on the income statement.
The fundamental analysis of Entera Bio is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Entera Bio includes many different criteria found on its balance sheet. For example, investors should never minimize Entera Bio's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Entera Bio's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Entera Bio.

Entera Bio Cash

Chance Of Financial Distress
Less than 47
Entera Bio has less than 47 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Entera Bio stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Entera Bio's official financial statements usually reflect Entera Bio's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Entera Bio. For example, before you start analyzing numbers published by Entera accountants, it's critical to develop an understanding of what Entera Bio's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Entera Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Entera Bio's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Entera Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Entera Bio. Please utilize our Beneish M Score to check the likelihood of Entera Bio's management to manipulate its earnings.

Entera Bio Company Summary

Entera Bio competes with Allovir. Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Entera Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 21 people.
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CUSIPM40527109
Older SymbolENTXW
LocationIsrael
Business AddressKiryat Hadassah Minrav
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.enterabio.com
Phone972 2 532 7151
Related EntityENTP
CurrencyUSD - US Dollar
You should never invest in Entera Bio without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Entera Stock, because this is throwing your money away. Analyzing the key information contained in Entera Bio's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Entera Bio Key Financial Ratios

Generally speaking, Entera Bio's financial ratios allow both analysts and investors to convert raw data from Entera Bio's financial statements into concise, actionable information that can be used to evaluate the performance of Entera Bio over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Entera Bio reports annually and quarterly.

Entera Bio Key Balance Sheet Accounts

201720182019202020212022 (projected)
Total Assets13.28 M13.34 M16.7 M9.72 M25.99 M21.91 M
Current Assets12.42 M12.47 M15.64 M9.11 M25.33 M21.09 M
Assets Non Current861 K875 K1.07 M613 K658 K692.07 K
Cash and Equivalents11.75 M7.51 M15.19 M8.59 M24.89 M20.06 M
Shareholders Equity(31.56 M)10.12 M11.92 M7.51 M22.57 M24.35 M
Total Liabilities44.84 M3.23 M4.78 M2.21 M3.42 M3.51 M
Current Liabilities2.02 M3.16 M4.59 M1.84 M3.16 M3.44 M

Entera Bio Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Entera Bio's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201720182019202020212022 (projected)
Consolidated Income(11.2 M)(10.3 M)(10.79 M)(11.22 M)(12.19 M)(13.15 M)
Earning Before Interest and Taxes EBIT(11.2 M)(10.3 M)(10.79 M)(11.2 M)(12.25 M)(13.21 M)
Earning Before Interest and Taxes USD(11.2 M)(10.3 M)(10.79 M)(11.2 M)(12.25 M)(13.21 M)
Net Income(11.2 M)(10.3 M)(10.79 M)(11.22 M)(12.19 M)(13.15 M)
Net Income Common Stock(11.2 M)(10.3 M)(10.79 M)(11.22 M)(12.19 M)(13.15 M)
Net Income Common Stock USD(11.2 M)(10.3 M)(10.79 M)(11.22 M)(12.19 M)(13.15 M)
Operating Expenses11.34 M11.36 M11.48 M11.23 M12.41 M12.63 M
Operating Income(11.34 M)(10.86 M)(11.45 M)(11.17 M)(12.22 M)(13.18 M)
Research and Development Expense2.77 M8.52 M7.2 M6.38 M6.77 M6.87 M
Selling General and Administrative Expense8.57 M2.84 M4.28 M4.85 M5.69 M5.79 M
Weighted Average Shares4.49 M7.96 M12.15 M18.42 M26.13 M20.86 M
Weighted Average Shares Diluted4.49 M7.98 M12.15 M18.42 M26.13 M21.08 M

Entera Bio Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Entera Bio. It measures of how well Entera is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Entera Bio brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Entera had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Entera Bio has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201720182019202020212022 (projected)
Capital Expenditure(51 K)(68 K)(40 K)(53 K)(17 K)(18.34 K)
Depreciation Amortization and Accretion43 K54 K238 K63 K53 K74.79 K
Net Cash Flow or Change in Cash and Cash Equivalents7.58 M(4.24 M)7.68 M(6.56 M)16.3 M17.59 M
Net Cash Flow from Financing11.11 M9.62 M12.65 M4.05 M25.38 M20.12 M
Net Cash Flow from Investing1 M(4.07 M)3.95 M(53 K)(17 K)(18.34 K)
Net Cash Flow from Operations(4.53 M)(9.8 M)(8.92 M)(10.56 M)(9.06 M)(9.78 M)
Share Based Compensation4.88 M1.23 M1.48 M901 K1.86 M1.81 M

Entera Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Entera Bio's current stock value. Our valuation model uses many indicators to compare Entera Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Entera Bio competition to find correlations between indicators driving Entera Bio's intrinsic value. More Info.
Entera Bio is rated # 2 in total debt category among related companies. It is one of the top stocks in price to sales category among related companies . The ratio of Total Debt to Price to Sales for Entera Bio is about  2,208 . Entera Bio Total Debt is fairly stable at the moment as compared to the past year. Entera Bio reported Total Debt of 302,000 in 2021. Comparative valuation analysis is a catch-all model that can be used if you cannot value Entera Bio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Entera Bio's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Entera Bio's earnings, one of the primary drivers of an investment's value.

Entera Bio Systematic Risk

Entera Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Entera Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Entera Bio correlated with the market. If Beta is less than 0 Entera Bio generally moves in the opposite direction as compared to the market. If Entera Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Entera Bio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Entera Bio is generally in the same direction as the market. If Beta > 1 Entera Bio moves generally in the same direction as, but more than the movement of the benchmark.
.

About Entera Bio Financials

What exactly are Entera Bio Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Entera Bio's income statement, its balance sheet, and the statement of cash flows. Potential Entera Bio investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Entera Bio investors may use each financial statement separately, they are all related. The changes in Entera Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Entera Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Entera Bio is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Entera grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Entera Bio August 11, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Entera Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Entera Bio. We use our internally-developed statistical techniques to arrive at the intrinsic value of Entera Bio based on widely used predictive technical indicators. In general, we focus on analyzing Entera Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Entera Bio's daily price indicators and compare them against related drivers.
Information Ratio(0.041842)
Maximum Drawdown32.9
Value At Risk(9.17)
Potential Upside8.38
Continue to Investing Opportunities. Note that the Entera Bio information on this page should be used as a complementary analysis to other Entera Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Entera Stock analysis

When running Entera Bio price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Is Entera Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entera Bio. If investors know Entera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entera Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
52.4 M
Quarterly Revenue Growth YOY
-0.57
Return On Assets
-0.42
Return On Equity
-1.0
The market value of Entera Bio is measured differently than its book value, which is the value of Entera that is recorded on the company's balance sheet. Investors also form their own opinion of Entera Bio's value that differs from its market value or its book value, called intrinsic value, which is Entera Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entera Bio's market value can be influenced by many factors that don't directly affect Entera Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entera Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Entera Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entera Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.